Brought to you by 
BioChem Therap. and XTL Biopharm. sign option agreement
13 Jul 1999
Executive Summary
BioChem Pharma Inc.'s BioChem Therapeutic Inc. (new agents for cancer, viral infections, etc.) signed an option agreement with XTL Biopharmaceuticals (cimeric animals) to investigate novel drugs for the treatment of hepatitis C in XTL's rodents.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Transgenics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioChem Therap. and XTL Biopharm. sign option agreement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice